Ignite Creation Date:
2025-12-24 @ 1:42 PM
Ignite Modification Date:
2025-12-27 @ 10:32 PM
Study NCT ID:
NCT04875195
Status:
COMPLETED
Last Update Posted:
2025-10-29
First Post:
2021-04-27
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-10-13
Completion Date Type:
ACTUAL
First Submit Date:
2021-04-27
First Submit QC Date:
None
Study First Post Date:
2021-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-12-05
Results First Submit QC Date:
None
Results First Post Date:
2025-02-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-27
Last Update Post Date:
2025-10-29
Last Update Post Date Type:
ESTIMATED